In this video interview, Michael Andreini, president and CEO of the Multiple Myeloma Research Foundation, talks unmet need in ...

Research from the Tufts Center for the Study of Drug Development’s PACT Consortium shows DCTs encourage higher participation ...

The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the efficacy of Winrevair (sotatercept-csrk) in treating pulmonary arterial ...

In this video interview, Michael Andreini, president and CEO of the Multiple Myeloma Research Foundation, highlights the ...

In year two of the trial, Elevidys demonstrated statistically significant and clinically improvements across three key ...

Being evaluated for the treatment of metastatic colorectal cancer, the combination regimen achieved an objective response ...

In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, highlights trial startup timelines and workforce ...

In this video interview, Michael Andreini, president and CEO of the Multiple Myeloma Research Foundation (MMRF), discusses the greatest challenges with clinical trials in multiple myeloma and how MMRF ...

Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve ...

In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, highlights increased data management, DE&I, and ...

Extended collaboration will further explore the capabilities of Medidata Platform from early-phase trials to post-marketing ...

In the Phase I dose escalation portion, which evaluated the combination in participants with small cell lung cancer, the first patient treated attained partial remission.